Kärkkäinen, Miia
Kettunen, Hannu-Pekka
Nurmi, Hanna
Selander, Tuomas
Purokivi, Minna
Kaarteenaho, Riitta
Funding for this research was provided by:
Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö (None, None, None, None)
The Organization for Respiratory Health in Finland (None, None)
Väinö and Laina Kivi Foundation (None, None)
The Kuopio Region Respiratory Foundation (None, None, None, None)
Jalmari and Rauha Ahokas Foundation (None)
Jalmari and Rauha Ahokas Foundation (None, None)
Center of Medicine and Clinical Research in Kuopio University Hospital (None)
the North Savo Regional Fund of the Finnish Cultural Foundation (None)
the state subsidy of the Kuopio University Hospital (None, None)
Research Director of Kuopio University Hospital (None)
Article History
Received: 24 September 2018
Accepted: 14 November 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: The study protocol was approved by the Research Ethics Committee of the Northern Savo Hospital District (statement 17/2013) and from the National Institute for Health and Welfare (Dnro THL/1052/5.05.01/2013). Permission to use data from death certificates was given by Statistics Finland (Dnro: TK-53-911-13). In this retrospective study, most of the patients were deceased and no consents to participate were gathered due to the register-based nature of research in accordance with Finnish legislation (Finlex, The Data Protection Act 1050/2018 (4 and 6 §)).
: Not Applicable.
: M.K. has received congress travel grants from Intermune, Boehringer-Ingelheim, Orion Pharma and Roche; lecture fee from Boehringer-Ingelheim; H. N. has received congress travel grants from Boehringer-Ingelheim, Roche and Orion Pharma; Consulting fees from Boehringer-Ingelheim and Roche Oy; H-P.K. received consulting fees from Roche Oy; M. P. has received travel grants from Boehringer-Ingelheim Finland Ltd., Takeda Leiras Ltd., Roche, personal fees from Boehringer-Ingelheim Finland Ltd., Chiesi, Intermune, Orion Pharma Ltd., Roche, Takeda Leiras Ltd.; T.S. has no conflicts of interest, R.K. has received congress and meeting travel costs from Orion Pharma, Roche and Boehringer-Ingelheim, consulting fees from GSK and lecture fees from Roche and Ratiopharm.